David Kirn - 14 Sep 2026 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: FDMT
Reported as of: 14 Sep 2026
Net transaction value: -$811,004
SEC form: 4
Accepted by SEC: 16 Sep 2026, 17:13:54 UTC
Prior SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Bizily as Attorney-in-Fact for David Kirn

Key filing fact

David Kirn filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 16 Sep 2026.

Key facts

This page summarizes David Kirn's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 17:13.

Change

Previous filing in this sequence was filed on 21 Aug 2026.
Current net transaction value: -$811,004.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834021 Primary reporting owner

Kirn David

Relationship: President and Chief Executive Officer, Director
Address: C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE
Signature: /s/ Scott Bizily as Attorney-in-Fact for David Kirn
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FDMT transaction

Common Stock

Sale

Transaction value: $811,004
Shares: -58,333
Change %: -7.1%
Price: $13.90
Shares after: 767,486
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

Footnote F2

The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC remarks

President and Chief Executive Officer